Sara Lewin, MD
Internal Medicine · San Francisco, CANPI 1558627059
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $60 of the $91 with a category attached, or 66.5%. 4 manufacturers reported payments, led by Pfizer at 33.5% of the total. 2024 is the largest year on record at $30, 2.1 times the $14 reported in 2020. That places this record below the midpoint for internal medicine clinicians in CA, where the typical reported total is $147.
Across 5 payments — averaging $18.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$30
- AbbVie$27
- Pentax Of America, Inc.$19
- Ironwood Pharmaceuticals, Inc$14
Across 170 payments — averaging $6336.10 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Takeda Pharmaceuticals U.S.A., Inc.$731K
- Janssen Research & Development, LLC$240K
- F. Hoffmann-la Roche AG$54K
- Genentech, Inc.$39K
- AbbVie$13K
What the payments were for
- Food & beverage$6066%
- Education$3034%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pfizer | 1 | $30 |
| AbbVie | 2 | $27 |
| Pentax Of America, Inc. | 1 | $19 |
| Ironwood Pharmaceuticals, Inc | 1 | $14 |
How this compares
$91 in reported general payments places this provider in the 40th percentile of 13,581 internal medicine providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Skyrizi On-BodyRisankizumab-Rzaa | 12 | $244,150 |
| XifaxanRifaximin | 18 | $45,986 |
| Mesalamine | 13 | $6,863 |
| Colesevelam Hcl | 19 | $2,292 |
| Omeprazole | 54 | $908 |
| Fluconazole | 18 | $881 |
| Dicyclomine Hcl | 26 | $525 |
| Mirtazapine | 13 | $357 |
| Famotidine | 20 | $299 |
| Diphenoxylate-AtropineDiphenoxylate Hcl/Atropine | 11 | $218 |
Paid to pharmacies, not to this prescriber.
Other internal medicine in San Francisco
- Fred CohenSan Francisco$929K
- John TeerlinkSan Francisco$819K
- Mark SmithSan Francisco$535K
- Lisa CapaldiniSan Francisco$434K
- Maria Dall'eraSan Francisco$417K
- Kenneth ColleySan Francisco$397K
- Louis CubbaSan Francisco$351K
- Daniel ButlerSan Francisco$347K
- Laurence CorashSan Francisco$336K
- Felicia StermanSan Francisco$298K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.